Encoded Therapeutics valuation, funding and investors
Encoded Therapeutics works in gene therapy development, based in South San Francisco, United States. Founded in 2014, it has about 192 employees.
Biotechnology Series F
VALUATION · TODAY
$3.55B +26% after Series F
Range $2.26B – $6.80B · Grade BTODAY
+12 MO
$2.00B
$4.00B
$6.00B
$8.00B
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series C $104M
Series D $135M
Series F $275M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY192 employees
+14%6m growth
+22%1y growth
−4%2y growth
100
200
300
Data from Jan 2021
Predicted in 1 yr $4.47B +26% vs today
Predicted next raise $492M if a round comes
Winding-down probability 0%
- Last round
- Series F · $275M · Sep 2026
- Valuation at last round
- $3.44B · implied
- Headcount
- 192 · up
- Grade
- B
- Founded
- 2014
Encoded Therapeutics valuation today
VCMC values Encoded Therapeutics at $3.6B today, with a range of $2.3B to $6.8B and a grade of B. The valuation starts from its last funding round, a Series F round in Sep 2026.
Valuation by date (158 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2014 | $5.01M | $1.83M – $13.8M | $5.25M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2014 | $5.03M | $1.83M – $13.8M | $5.28M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2014 | $5.05M | $1.84M – $13.9M | $5.29M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2014 | $5.07M | $1.85M – $13.9M | $5.32M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2014 | $5.09M | $1.85M – $14.0M | $5.34M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2014 | $5.11M | $1.86M – $14.0M | $5.36M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2014 | $5.13M | $1.87M – $14.1M | $5.38M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2014 | $5.15M | $1.88M – $14.2M | $5.40M (+5%) | before first round | – | unknown | D | 0% |
| 1 Sep 2014 | $5.17M | $1.88M – $14.2M | $5.42M (+5%) | before first round | – | unknown | D | 0% |
| 1 Oct 2014 | $5.19M | $1.89M – $14.3M | $5.44M (+5%) | before first round | – | unknown | D | 0% |
| 1 Nov 2014 | $5.21M | $1.90M – $14.3M | $5.46M (+5%) | before first round | – | unknown | D | 0% |
| 1 Dec 2014 | $5.23M | $1.91M – $14.4M | $5.48M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2015 | $5.25M | $1.91M – $14.4M | $5.51M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2015 | $5.28M | $1.92M – $14.5M | $5.53M (+5%) | before first round | – | unknown | D | 0% |
| 1 Mar 2015 | $5.29M | $1.93M – $14.5M | $5.55M (+5%) | before first round | – | unknown | D | 0% |
| 1 Apr 2015 | $5.32M | $1.93M – $14.6M | $5.57M (+5%) | before first round | – | unknown | D | 0% |
| 1 May 2015 | $5.34M | $1.94M – $14.7M | $5.59M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jun 2015 | $5.36M | $1.95M – $14.7M | $5.61M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jul 2015 | $5.38M | $1.96M – $14.8M | $5.64M (+5%) | before first round | – | unknown | D | 0% |
| 1 Aug 2015 | $5.40M | $1.97M – $14.8M | $5.78M (+7%) | before first round | – | unknown | D | 0% |
| 1 Sep 2015 | $5.42M | $1.97M – $14.9M | $5.94M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2015 | $5.44M | $1.98M – $14.9M | $6.09M (+12%) | before first round | – | unknown | D | 0% |
| 1 Nov 2015 | $5.46M | $1.99M – $15.0M | $6.26M (+15%) | before first round | – | unknown | D | 0% |
| 1 Dec 2015 | $5.48M | $2.00M – $15.1M | $6.42M (+17%) | before first round | – | unknown | D | 0% |
| 1 Jan 2016 | $5.51M | $2.00M – $15.1M | $6.60M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.53M | $2.01M – $15.2M | $6.78M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.55M | $2.02M – $15.2M | $6.95M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.57M | $2.03M – $15.3M | $7.14M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.59M | $2.04M – $15.4M | $7.33M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.61M | $2.04M – $15.4M | $7.53M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.64M | $2.05M – $15.5M | $7.72M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.79M | $2.11M – $15.9M | $7.93M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.94M | $2.16M – $16.3M | $8.15M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.10M | $2.22M – $16.8M | $8.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.26M | $2.28M – $17.2M | $8.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.43M | $2.34M – $17.7M | $8.81M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 27 Jun 2019 | $946M | $621M – $1.9B | $1.2B (+30%) | after a round | – | unknown | B | 0% |
| 1 Jul 2019 | $949M | $621M – $1.9B | $1.2B (+30%) | after a round | – | unknown | B | 0% |
| 1 Aug 2019 | $970M | $621M – $1.9B | $1.2B (+27%) | after a round | – | unknown | B | 0% |
| 1 Sep 2019 | $992M | $621M – $1.9B | $1.2B (+24%) | after a round | – | unknown | B | 0% |
| 1 Oct 2019 | $1.0B | $621M – $1.9B | $1.2B (+21%) | after a round | – | unknown | B | 0% |
| 1 Nov 2019 | $1.0B | $621M – $1.9B | $1.2B (+19%) | after a round | – | unknown | B | 0% |
| 1 Dec 2019 | $1.1B | $621M – $1.9B | $1.2B (+16%) | after a round | – | unknown | B | 0% |
| 1 Jan 2020 | $1.1B | $621M – $1.9B | $1.2B (+13%) | after a round | – | unknown | B | 0% |
| 1 Feb 2020 | $1.1B | $621M – $1.9B | $1.2B (+11%) | after a round | – | unknown | B | 0% |
| 1 Mar 2020 | $1.1B | $621M – $1.9B | $1.2B (+9%) | after a round | – | unknown | B | 0% |
| 1 Apr 2020 | $1.2B | $621M – $1.9B | $1.2B (+6%) | after a round | – | unknown | B | 0% |
| 1 May 2020 | $1.2B | $621M – $1.9B | $1.2B (+4%) | after a round | – | unknown | B | 0% |
| 1 Jun 2020 | $1.2B | $621M – $1.9B | $1.2B (+2%) | after a round | – | unknown | B | 0% |
| 1 Jul 2020 | $1.2B | $616M – $1.9B | $1.2B (0%) | after a round | – | unknown | B | 0% |
| 23 Jul 2020 | $1.5B | $1.1B – $2.8B | $2.0B (+30%) | after a round | – | unknown | B | 0% |
| 1 Aug 2020 | $1.5B | $1.1B – $2.8B | $2.0B (+29%) | after a round | – | unknown | B | 0% |
| 1 Sep 2020 | $1.6B | $1.1B – $2.8B | $2.0B (+26%) | after a round | – | unknown | B | 0% |
| 1 Oct 2020 | $1.6B | $1.1B – $2.8B | $2.0B (+24%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $1.6B | $1.1B – $2.8B | $2.0B (+21%) | after a round | – | unknown | B | 0% |
| 1 Dec 2020 | $1.7B | $1.1B – $2.8B | $2.0B (+18%) | after a round | – | unknown | B | 0% |
| 1 Jan 2021 | $1.7B | $1.1B – $2.8B | $2.0B (+16%) | after a round | 100 | unknown | B | 0% |
| 1 Feb 2021 | $1.8B | $1.1B – $2.8B | $2.0B (+13%) | after a round | 100 | unknown | B | 0% |
| 1 Mar 2021 | $1.8B | $1.1B – $2.8B | $2.0B (+11%) | after a round | 100 | unknown | B | 0% |
| 1 Apr 2021 | $1.8B | $1.1B – $2.8B | $2.0B (+8%) | after a round | 100 | flat | B | 0% |
| 1 May 2021 | $1.9B | $1.1B – $2.8B | $2.0B (+6%) | after a round | 100 | flat | B | 0% |
| 1 Jun 2021 | $1.9B | $1.1B – $2.8B | $2.0B (+4%) | after a round | 100 | flat | B | 0% |
| 1 Jul 2021 | $2.0B | $1.1B – $2.8B | $2.0B (+2%) | after a round | 100 | flat | B | 0% |
| 1 Aug 2021 | $2.0B | $1.1B – $2.8B | $2.0B (0%) | after a round | 100 | flat | B | 0% |
| 1 Sep 2021 | $2.0B | $1.0B – $2.8B | $2.0B (0%) | after a round | 100 | flat | B | 0% |
| 1 Oct 2021 | $2.0B | $966M – $2.8B | $2.0B (0%) | after a round | 100 | flat | B | 0% |
| 1 Nov 2021 | $2.0B | $922M – $2.8B | $2.0B (0%) | after a round | 100 | flat | B | 0% |
| 1 Dec 2021 | $2.0B | $882M – $2.8B | $2.0B (0%) | after a round | 100 | flat | B | 0% |
| 1 Jan 2022 | $2.0B | $842M – $2.8B | $2.0B (0%) | after a round | 100 | flat | C | 0% |
| 1 Feb 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Mar 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Apr 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 May 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Jun 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Jul 2022 | $2.3B | $1.3B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Aug 2022 | $2.3B | $1.2B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Sep 2022 | $2.3B | $1.2B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Oct 2022 | $2.3B | $1.2B – $3.2B | $2.3B (0%) | after a round | 180 | growing | B | 0% |
| 1 Nov 2022 | $2.3B | $568M – $3.2B | $2.3B (0%) | after a round | 180 | unknown | C | 0% |
| 1 Dec 2022 | $2.3B | $541M – $3.2B | $2.3B (0%) | after a round | 180 | unknown | C | 0% |
| 1 Jan 2023 | $2.3B | $905M – $3.3B | $2.2B (-3%) | after a round | 200 | up | C | 0% |
| 1 Feb 2023 | $2.3B | $888M – $3.3B | $2.2B (-3%) | after a round | 200 | up | C | 0% |
| 1 Mar 2023 | $2.3B | $873M – $3.3B | $2.2B (-4%) | after a round | 200 | up | C | 0% |
| 1 Apr 2023 | $2.3B | $857M – $3.3B | $2.2B (-4%) | after a round | 200 | up | C | 0% |
| 1 May 2023 | $2.3B | $841M – $3.3B | $2.2B (-5%) | after a round | 200 | up | C | 0% |
| 1 Jun 2023 | $2.3B | $825M – $3.3B | $2.2B (-5%) | after a round | 200 | up | C | 0% |
| 1 Jul 2023 | $2.3B | $810M – $3.3B | $2.2B (-6%) | after a round | 200 | up | C | 0% |
| 1 Aug 2023 | $2.3B | $629M – $3.3B | $2.2B (-6%) | after a round | 200 | up | C | 0% |
| 1 Sep 2023 | $2.3B | $353M – $3.3B | $2.3B (0%) | after a round | 200 | unknown | D | 0% |
| 1 Oct 2023 | $1.7B | $332M – $3.2B | $1.4B (-18%) | after a round | 190 | flat | D | 26% |
| 1 Nov 2023 | $1.7B | $315M – $3.2B | $1.4B (-18%) | after a round | 190 | flat | D | 26% |
| 1 Dec 2023 | $1.7B | $300M – $3.2B | $1.4B (-18%) | after a round | 190 | flat | D | 26% |
| 1 Jan 2024 | $1.6B | $285M – $3.1B | $1.4B (-18%) | after a round | 190 | flat | D | 26% |
| 1 Feb 2024 | $1.6B | $271M – $3.1B | $1.3B (-18%) | after a round | 190 | flat | D | 26% |
| 1 Mar 2024 | $1.6B | $259M – $3.1B | $1.3B (-19%) | after a round | 190 | flat | D | 27% |
| 1 Apr 2024 | $1.5B | $246M – $3.1B | $1.3B (-19%) | after a round | 190 | flat | D | 27% |
| 1 May 2024 | $1.5B | $234M – $3.1B | $1.2B (-19%) | after a round | 190 | flat | D | 27% |
| 1 Jun 2024 | $1.5B | $222M – $3.0B | $1.2B (-19%) | after a round | 190 | flat | D | 27% |
| 1 Jul 2024 | $1.5B | $214M – $3.1B | $1.3B (-17%) | after a round | 200 | flat | D | 25% |
| 1 Aug 2024 | $1.5B | $203M – $3.1B | $1.3B (-13%) | after a round | 200 | flat | D | 23% |
| 1 Sep 2024 | $1.6B | $193M – $3.1B | $1.4B (-12%) | after a round | 200 | flat | D | 21% |
| 1 Oct 2024 | $1.6B | $184M – $3.0B | $1.4B (-11%) | after a round | 200 | flat | D | 20% |
| 1 Nov 2024 | $1.6B | $175M – $3.0B | $1.4B (-10%) | after a round | 200 | flat | D | 18% |
| 1 Dec 2024 | $1.6B | $166M – $3.0B | $1.5B (-9%) | after a round | 200 | flat | D | 17% |
| 1 Jan 2025 | $1.6B | $158M – $3.0B | $1.5B (-9%) | after a round | 200 | flat | D | 15% |
| 1 Feb 2025 | $1.6B | $150M – $3.0B | $1.5B (-8%) | after a round | 200 | flat | D | 14% |
| 1 Mar 2025 | $1.7B | $144M – $2.9B | $1.5B (-8%) | after a round | 200 | flat | D | 13% |
| 1 Apr 2025 | $1.7B | $136M – $2.9B | $1.5B (-7%) | after a round | 200 | flat | D | 12% |
| 1 May 2025 | $1.7B | $130M – $2.9B | $1.5B (-7%) | after a round | 200 | flat | D | 11% |
| 1 Jun 2025 | $1.7B | $125M – $2.9B | $1.6B (-7%) | after a round | 200 | flat | D | 10% |
| 1 Jul 2025 | $1.7B | $125M – $2.8B | $1.6B (-7%) | after a round | 200 | flat | D | 9% |
| 1 Aug 2025 | $427M | $120M – $3.1B | $352M (-18%) | after a round | 163 | down | D | 91% |
| 1 Sep 2025 | $383M | $119M – $3.1B | $312M (-18%) | after a round | 158 | down | D | 97% |
| 1 Oct 2025 | $382M | $119M – $3.1B | $312M (-18%) | after a round | 158 | down | D | 97% |
| 1 Nov 2025 | $383M | $119M – $3.1B | $313M (-18%) | after a round | 159 | down | D | 97% |
| 1 Dec 2025 | $383M | $119M – $3.1B | $313M (-18%) | after a round | 159 | down | D | 97% |
| 1 Jan 2026 | $383M | $119M – $3.1B | $313M (-18%) | after a round | 159 | down | D | 97% |
| 1 Feb 2026 | $383M | $119M – $3.1B | $313M (-18%) | after a round | 159 | down | D | 97% |
| 1 Mar 2026 | $382M | $119M – $3.1B | $313M (-18%) | after a round | 159 | down | D | 97% |
| 1 Apr 2026 | $387M | $120M – $3.1B | $316M (-18%) | after a round | 168 | down | D | 97% |
| 1 May 2026 | $387M | $120M – $3.1B | $316M (-18%) | after a round | 168 | down | D | 97% |
| 1 Jun 2026 | $440M | $121M – $3.1B | $364M (-17%) | after a round | 171 | flat | D | 89% |
| 1 Jul 2026 | $491M | $121M – $3.0B | $412M (-16%) | after a round | 171 | flat | D | 82% |
| 1 Aug 2026 | $464M | $121M – $2.0B | $461M (-1%) | after a round | 171 | flat | D | 76% |
| 1 Sep 2026 | $516M | $121M – $2.0B | $512M (-1%) | after a round | 171 | flat | D | 70% |
| 10 Sep 2026 | $3.4B | $2.3B – $6.8B | $4.5B (+30%) | after a round | 171 | flat | B | 0% |
| 1 Oct 2026 | $3.5B | $2.3B – $6.8B | $4.5B (+28%) | after a round | 192 | up | B | 0% |
| 24 Oct 2026 | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | after a round | 192 | up | B | 0% |
Key facts about Encoded Therapeutics
- Founded
- 2014
- Headquarters
- South San Francisco, United States
- Employees
- about 192 +22% in a year
- Total raised
- $514M
- Funding rounds
- 3
- Last round
- Series F Sep 2026
Encoded Therapeutics was founded in 2014 by Kartik Ramamoorthi and Stephanie Tagliatela.
Encoded Therapeutics funding history
Encoded Therapeutics has 3 funding rounds on record, from Jun 2019 to Sep 2026, $514M in total. None disclosed a valuation.
Series F 9 Sep 2026
Led by GV, Undisclosed healthcare fund, another healthcare fund; with ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund, Venrock.
Sources: encoded.com, encoded.com, finance.yahoo.com and 4 more
$275M
Series D 22 Jul 2020
Led by GV; with Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon, SoftBank Vision Fund.
Sources: encoded.com, encoded.com, globalgenes.org and 3 more
$135M
Series C 26 Jun 2019
Led by Venrock; with ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, Altitude Life Science Ventures, Menlo Ventures, RTW Investments, Boxer Capital, Alexandria Venture Investments.
Sources: encoded.com, fiercebiotech.com, prnewswire.com and 2 more
$104M
Encoded Therapeutics investors
20 investors have backed Encoded Therapeutics; GV, Venrock and another healthcare fund and 1 more led at least one round.
- GV lead, 2 rounds
- Venrock lead, 2 rounds
- another healthcare fund lead
- Undisclosed healthcare fund lead
- ARCH Venture Partners 3 rounds
- Matrix Capital Management 3 rounds
- Menlo Ventures 2 rounds
- SoftBank Vision Fund 2 rounds
- Alexandria Venture Investments
- Altitude Life Science Ventures
- HBM Genomics
- Invus
- Janus Henderson Investors
- Meritech Capital
What Encoded Therapeutics does
Encoded Therapeutics works in biotechnology, with 12 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Encoded Therapeutics, Inc. is an American biotechnology company engaged in the development of gene therapies for pediatric central nervous system disorders and other neurological conditions. The company utilizes proprietary cell-selective targeting and regulation platforms to create gene therapies with enhanced specificity and cell selectivity, and is advancing a pipeline of therapies for liver, metabolic, and cardiovascular disorders. Encoded Therapeutics also conducts clinical research and collaborates with partners to expand its therapeutic portfolio.
Description from Veridion's company data.
Products and services
- Gene Therapy Development
- Pediatric CNS Disorder Therapy Development
- Neurological Disorder Therapy Development
- Liver and Metabolic Disorder Therapy Development
- Cardiovascular Disorder Therapy Development
- Cell-Selective Targeting Platform Development
- Gene Therapy Delivery System Development
- Therapeutic Transgene Regulation Platform Development
- Multiplex Staining Research Services
- Clinical Trial Execution for Gene Therapies
- Gene Therapy Platform Licensing and Collaboration Services
- Sustainable Gene Therapy Innovation Services
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Cell-Selective Targeting and Regulation Platform
- Therapeutic Transgene Expression Control
- Multiplex Staining for Gene Therapy Development
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Encoded Therapeutics
What is Encoded Therapeutics worth?
Valuation $3.6B (range $2.3B to $6.8B), as of 24 Oct 2026.
Has Encoded Therapeutics raised money?
Encoded Therapeutics has 3 funding rounds on record, from Jun 2019 to Sep 2026, $514M in total. None disclosed a valuation.
Who has invested in Encoded Therapeutics?
GV, Venrock, another healthcare fund, Undisclosed healthcare fund, ARCH Venture Partners and Illumina Ventures, and 14 more. Lead investors include GV, Venrock, another healthcare fund and Undisclosed healthcare fund.
How many people work at Encoded Therapeutics?
About 192, up 22% over the last year. Headcount grew from 100 in Jan 2021 to 192 in Sep 2026.
What does Encoded Therapeutics do?
Encoded Therapeutics works in biotechnology, with 12 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are gene therapy development, pediatric CNS disorder therapy development and neurological disorder therapy development.
When was Encoded Therapeutics founded, and where is it based?
Encoded Therapeutics was founded in 2014 and is based in South San Francisco, United States. It has about 192 employees, up 22% over the last year.